Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis. (PubMed, Front Oncol) - Oct 18, 2026 - "The NMA results showed that, compared to ipilimumab, pembrolizumab, nivolumab, nivolumab + relatlimab, and nivolumab + ipilimumab demonstrated significant advantages in improving OS...In the PFS analysis, this regimen had the highest SUCRA value only within the connected network consisting of dacarbazine, nivolumab, and the combination of nivolumab and relatlimab (SUCRA = 98.86%), although no comparisons or standardized rankings were performed between different PFS networks...They are intended solely to generate research hypotheses and should not be interpreted as evidence of superiority over other treatments or as a basis for changing the current standard of care. Direct head-to-head RCTs are still needed to further clarify the comparative efficacy of the relevant regimens."
Journal • Retrospective data • Review • Melanoma • Oncology • Solid Tumor • BRAF
|
|
Xiaoqi Tan; Yishan Zhou; Yuanmin He
|